Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily

NCT00214435 is registered in ClinicalTrials.gov with 407 Doctors as lead sponsor.

NCT NCT00214435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00214435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily
Lead sponsor
407 Doctors
Phase
Phase 4
Overall status
Unknown status
Start date
May 31, 2004
Completion date
Not reported
Enrollment
120
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aids, hiv infection